How accelerated atherosclerosis in SLE has changed our management of the disorder

Lupus

Volumn 9, Issue 3, 2000, Pages 228-231

  Hallegua, David S ^a,b   Wallace, D J ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Coronary artery disease (CAD); Corticosteroids (CS); Systemic lupus erythematosus (SLE)

Indexed keywords

ANTILIPEMIC AGENT; HOMOCYSTEINE; PHOSPHOLIPID ANTIBODY;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; EXERCISE; HYPERGLYCEMIA; HYPERTENSION; MORTALITY; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0034032312     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828181     Document Type: Short Survey

References (39)

1. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term follow-up of an inception cohort. Arthritis Rheum 1995; 38(10): 1492-1499.
2. Jacobsen S, Petersen J, Ullman S et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factos of prognostic value. Clin Rheumatol 1998; 17(6): 478-484.
3. Koh ET, Seow A, Leong KH, Chng HH. SLE mortality in an oriental population. Lupus 1997; 6(1): 27-31.
4. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93(5): 513-519.
5. Kannel WB, Castelle WP, Gordon T, McNamara PM. Serum lipoproteins and the risk of coronary artery disease. Ann Intern Med 1971; 74: 1-12.
6. Roussouw JE. The effects of lowering serum cholesterol on coronary heart disease risk. Med Clin North Am 1994; 78: 181-195.
7. MacGregor AJ, Dhillon VB, Binder A et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992; 51(2): 152-155.
8. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. 1988; 148(1): 36-69.
9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
10. Manninen V, Elo MO, Frick KH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-651.
11. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention trials. 1. Reduction in incidence of coronary artery disease. JAMA 1984; 251: 351-364.
12. Coronary Drug Project Research Group. Clofibrate and Niacin in coronary artery disease. JAMA 1975; 231: 360-381.
13. Wallace DJ, Podell T, Weiner J et al. Lupus nephritis: experience with 230 patients in a private practice from 1950-1980. Am J Med 1982; 72: 209-220.
14. Wallace DJ, Metzger AL, Stecher VJ et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89(3): 322-326.
15. Rahman P, Gladman DD, Urowitz MB et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26(2): 325-330.
16. Tsakonas E, Joseph L, Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7(2): 80-85.
17. van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995; 38: 1826-1831.
18. Tam LS, Li EK, Leung CB et al. Long-term treatement of lupus nephritis with cyclosporin A. QJM 1998; 91(8): 573-580.
19. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10(4): 833-839.
20. Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol 1998; 25(2): 243-246.
21. Boumpas DT, Austin HA III, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340(8822): 741-745.
22. Petri M, Roubenoff R, Dallal GE et al. Plama homocysteine as a risk facto for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348(9035): 1120-1124.
23. Fijnheer R, Roest M, Haas FJ et al. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol 1998; 25(9): 1737-1742.
24. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36(11): 1566-1574.
25. Greisman SG, Thayaparan RS, Godwin TA, Lockshin MD. Occlusive vasculopathy in systemic lupus erythematosus. Association with anticardioilipin antibody. Arch Intern Med 1991; 151: 389-392.
26. Cowchock SG, Reece EA, Balaban D et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment. Am J Obstet Gynecol 1992; 166: 1318-1323.
27. Vaarala O, Puurunen M, Likka M et al. Affinity purified cardiolipin binding antibodies show heterogeneity in their binding to oxidized low density lipoprotein. Clin Exp Immunol 1996; 104: 269-274.
28. Horkko S, Miller E, Dudi E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest 1996; 98: 815-825.
29. Hasunma Y, Matsuura E, Makita Z et al. Involvement of beta-2 glycoprotein 1 and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-573.
30. George J, Afek A, Gilburd B et al. Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 1997; 6: 723-729.
31. Bruce IN, Gladman DD, Urowitz MB. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 1998; 16(4): 435-440.
32. Meacham LR, Abdul-Latif H, Sullivan K, Culler FL. Predictors of change in insulin sensitivity during glucocorticoid treatment. Horm Metab Res 1997; 29(4): 172-175.
33. Ginzler EM, Felson DT, Anthony JM, Anderson JJ. Hypertension increases the risk of renal deterioration in systemic lupus erythematosus. J Rheumatol 1993; 20(10): 1694-1700.
34. Naiker IP, Chrystal V, Randeree IGH, Seedat YK. The significance of arterial hypertension at the onset of clinical lupus nephritis. Postgrad Med J 1997; 73: 230-233.
35. Petri M. Smoking is a risk factor for musculoskeletal, pulmonary and cardiac disease in systemic lupus erythematosus. Lupus 1998; 7: (S1) 61.
36. Brown K, Petri M, Goldman D. Cutaneous manifestations of SLE: Associations with other manifestations of SLE and with smoking. Arthritis Rheum 1996; 39: S291.
37. Rahman P, Goldman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25: 1716-1719.
38. Ramsey-Goldman R, Chang RW, Dunlop D et al. Exercise in patients with systemic lupus erythematosus (SLE): Pilot study. Arthritis Rheum 1995; 38: S242.
39. Sturfelt G, Eskilsson J, Nived O et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine (Baltimore) 1992; 71(4): 216-223.